Imaging Endpoints Uses AG Mednet Software to Reduce Queries
According to industry research, more than half of all image-related clinical trial query stoppages result from preventable human errors that can delay a trial for up to seven weeks. AG Mednet's Submission Quality and Compliance software detects errors that result in query stoppages.
AG Mednet and imaging core lab services provider Imaging Endpoints have partnered to allow Imaging Endpoints to use AG Mednet's Submission Quality and Compliance software for oncology, neurology, musculoskeletal and cardiovascular clinical trials.
According to industry research, more than half of all image-related clinical trial query stoppages result from preventable human errors that can delay a trial for up to seven weeks. AG Mednet's Submission Quality and Compliance software can detect errors that result in query stoppages and gives core labs a system to verify information, automatically update support systems including EDC (electronic data capture) to reduce the amount of queries returned for correction or re-scanning.
Link here for the full press release.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
